Solasia Pharma K.K. develops drugs in the field of oncology in Asia.
Flawless balance sheet and overvalued.
Share Price & News
How has Solasia Pharma K.K's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 4597's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 4597 underperformed the JP Biotechs industry which returned -27% over the past year.
Return vs Market: 4597 underperformed the JP Market which returned -15.7% over the past year.
Price Volatility Vs. Market
How volatile is Solasia Pharma K.K's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Solasia Pharma K.K undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 4597's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 4597's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 4597 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 4597 is unprofitable, so we can't compare its PE Ratio to the JP market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 4597's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 4597 is good value based on its PB Ratio (1.8x) compared to the JP Biotechs industry average (4x).
How is Solasia Pharma K.K forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Solasia Pharma K.K has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Solasia Pharma K.K's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Solasia Pharma K.K performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 4597 is currently unprofitable.
Growing Profit Margin: 4597 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 4597 is unprofitable, and losses have increased over the past 5 years at a rate of -27.3% per year.
Accelerating Growth: Unable to compare 4597's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4597 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-0.7%).
Return on Equity
High ROE: 4597 has a negative Return on Equity (-26.99%), as it is currently unprofitable.
How is Solasia Pharma K.K's financial position?
Financial Position Analysis
Short Term Liabilities: 4597's short term assets (¥4.3B) exceed its short term liabilities (¥925.0M).
Long Term Liabilities: 4597's short term assets (¥4.3B) exceed its long term liabilities (¥104.0M).
Debt to Equity History and Analysis
Debt Level: 4597 is debt free.
Reducing Debt: 4597 has no debt compared to 5 years ago when its debt to equity ratio was 519.6%.
Inventory Level: 4597 has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 4597's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4597 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 4597 has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of -23.2% each year.
What is Solasia Pharma K.K's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 4597's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 4597's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 4597's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 4597's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 4597's dividend in 3 years as they are not forecast to pay a notable one for the JP market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Yoshihiro Arai (59yo)
Mr. Yoshihiro Arai has been the President and Representative Director at Solasia Pharma KK since February 2013. Mr. Arai served as Executive Vice President of Development of JapanBridge, Inc. since Septemb ...
|President & Representative Director||7.17yrs||no data||0.46% ¥58.1m|
|CFO & Director||4.33yrs||no data||0.37% ¥45.9m|
|External Director||11.92yrs||no data||0.072% ¥9.0m|
|External Corporate Auditor||no data||no data||no data|
|Independent Outside Director||no data||no data||no data|
|Independent Outside Director||3.92yrs||no data||no data|
|External Director||no data||no data||no data|
|Full-Time External Corporate Auditor||no data||no data||no data|
|External Director||no data||no data||no data|
|Independent Outside Director||0.083yr||no data||no data|
Experienced Board: 4597's board of directors are considered experienced (4.3 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.8%.
Solasia Pharma K.K.'s company bio, employee growth, exchange listings and data sources
- Name: Solasia Pharma K.K.
- Ticker: 4597
- Exchange: TSE
- Founded: 2006
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: JP¥12.574b
- Shares outstanding: 116.43m
- Website: https://www.solasia.co.jp
Number of Employees
- Solasia Pharma K.K.
- Sumitomo Fudosan Shiba-Koen Tower
- 4th Floor
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|4597||TSE (The Tokyo Stock Exchange)||Yes||Common Shares||JP||JPY||Mar 2017|
|9SO||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Mar 2017|
Solasia Pharma K.K. develops drugs in the field of oncology in Asia. The company offers episil oral liquid for the control and relief of pain; and Sancuso, a transdermal delivery system that delivers granisetron, an anti-emetic into the patient’s bloodstream for the treatment of chemotherapy induced nausea and vomiting. It is also developing SP-02, a mitochondrial-targeted agent, which is in Phase II clinical study to treat various hematologic and solid cancers; and SP-04, which has completed phase IIb clinical trials for chemotherapy induced peripheral neuropathy. The company was founded in 2006 and is based in Tokyo, Japan.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/02 19:09|
|End of Day Share Price||2020/04/02 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.